Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer

<div>Flow cytometric analysis on changes in the immune function of patients with better prognosis in the treatment group (it represents the change of CD4/CD8 ratio during the effective treatment of patients, and the ratio is getting higher and higher. Three continuous flow charts of typical patients were used here).</div>

Journal of Oncology

fig7

Figure 7

Figure 7: Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer 

Figure 7 | Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer 